

Our Ref: 234/2023
MAY 2023

Re: Your request made under the Freedom of Information Act 2000

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept - 806

Bevacizumab - 32

Brolucizumab - 0

Dexamethasone - 9

Faricimab - 0

Ranibizumab - 16

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Faricimab

Ranibizumab

Unable to answer this question using the pharmacy system, an audit of each individual patient record would be required which is not achievable within the timescale of the Freedom of Information Act 2000.